Evidence map›Paper›PMID 40579003›Full record

ArticleIn vivo (Athens, Greece)

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

Yujiro Nagata, Takaomi Sugi, Sohei Yamamura, Yoshihiro Sugita, Yui Mizushima, Takuo Matsukawa, Tomohisa Takaba, Kazumasa Jojima, Katsuyoshi Higashijima, Masahiro Matsumoto and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yujiro NagataDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; yujiro-nagata@med.uoeh-u.ac.jp.
Takaomi SugiDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Sohei YamamuraDepartment of Urology, Wakamatsu Hospital of University of Occupational and Environmental Health, Kitakyushu, Japan.
Yoshihiro SugitaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yui MizushimaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Takuo MatsukawaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Tomohisa TakabaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kazumasa JojimaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Katsuyoshi HigashijimaDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masahiro MatsumotoDepartment of Urology, Wakamatsu Hospital of University of Occupational and Environmental Health, Kitakyushu, Japan.
Akinori MinatoDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Ikko TomisakiDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Eiji KashiwagiDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Naohiro FujimotoDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCurrently, there are no established predictive or prognostic biomarkers for first-line enzalutamide (ENZ) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to assess the predictive and prognostic significance of the initial-to-nadir prostate-specific antigen (PSA) ratio (I/N PSA) during primary androgen-deprivation therapy for PATIENTS AND

methodsA total of 33 patients with mCRPC receiving first-line enzalutamide were included in the study to investigate the correlation between I/N PSA in combined androgen blockade and clinical outcomes. Patients were dichotomized by median I/N PSA values. A PSA response was defined as a 90% or greater decline in PSA levels following the initiation of ENZ treatment in patients with mCRPC.

resultsThe median I/N PSA was 382. In the high I/N PSA (≥382) group, the PSA response rate was 75.0%, significantly higher than that in the low I/N PSA group (35.3%;

conclusionIn patients with mCRPC, the I/N PSA is a promising predictive and prognostic biomarker for first-line ENZ treatment and may provide personalized approaches in daily practice.

Indexed as

Androgen AntagonistsPhenylthiohydantoinProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overBenzamidesBiomarkers, TumorHumansMaleMiddle AgedNeoplasm MetastasisNitrilesPrognosisTreatment OutcomeAndrogen AntagonistsBenzamidesBiomarkers, TumorenzalutamideNitrilesPhenylthiohydantoinProstate-Specific Antigenandrogen-deprivation therapyCastration-resistant prostate cancerenzalutamideinitial-to-nadir prostate-specific antigen ratio

Identifiers

PMID40579003
PMCPMC12223648

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.